Influence. Innovate. Growth. ASTCT President Margaret MacMillan, MD, MSc, FRCPC and Past President David Porter, MD, discuss the future of ASTCT and the priorities shaping our 2026–2028 Strategic Plan. Watch to learn more: youtube.com/watch?v=yFvlNPvj…

In this ASTCT Board Member Spotlight, Sophie Paczesny, MD, PhD, reflects on her work advancing GVHD biomarker research and immunotherapy innovation, shares her priorities as an ASTCT board member and offers insights on the current opportunities and challenges in the field. Read the full spotlight: ow.ly/vpkP50Z8BGz

At this upcoming ASTCT Cord Blood SIG webinar on July 1, researchers will discuss the role of cord blood as a graft source for patients with difficult-to-cure acute leukemia, exploring clinical outcomes and real-world applications through roundtable discussion. Register now and join colleagues for a conversation on the latest developments in cord blood transplantation: ow.ly/ONCc50Z8BFc

The #Tandem27 Pharmacy Track is seeking speakers for the 2027 meetings in Orlando! Topics for 2027 include grants, solid tumors, gene therapy, GVHD and more. Visit the link below to learn more and apply by Friday, July 3. Apply now: surveymonkey.com/r/DG9WXQZ

ASTCT's comment letter responding to the @CMSGov FY 2027 IPPS Proposed Rule is now available to view. Read the letter to review the Society’s recommendations for CMS: astct.org/Advocacy/Policy-Le…

The June issue of 'Transplantation and Cellular Therapy,' is now available online: astctjournal.org/current @ELShematology

This special GVHD supplement explores the diagnosis and treatment of cutaneous cGVHD, warning signs of ocular GVHD and the importance of addressing the physical and psychosocial needs of patients with GVHD. Read in English: ow.ly/60eE50Z8l23 Read in Spanish: ow.ly/TVeR50Z8l21

For 30 years, 'Transplantation and Cellular Therapy' has advanced the science and practice of HCT and cellular therapies. @ASTCT_Journal ASTCT President Margy MacMillan reflects on the journal's impact and continued importance to the field. ow.ly/5kSm50Z8jwa

Explore two hot topics with the ASTCT Pharmacy SIG! Join the journal club to discuss: ✅Brexucabtagene autoleucel in BTKi naive relapsed/refractory mantle cell lymphoma ✅Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide maintenance post transplant in multiple myeloma Register today: ow.ly/yfPk50Z8joQ

In our latest episode of ASTCT Talks, Dr. Nirali Shah is joined by Dr. Christy Duncan and Dr. Sung‑Yun Pai to talk through recent progress in the field and what it actually takes to deliver these treatments at the patient level. The discussion draws on their experience in transplant and genetic disease, covering both scientific advances and the operational challenges that come with implementing gene therapy—especially in complex and resource‑intensive settings. Listen now on Nucleus or wherever you get your podcasts. astct.org/Nucleus/Article/po…

Dr. Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, is the first author of the article “From Vision to Viability: Developing Infrastructure for Cell and Gene Therapy Programs.” She shares in this Q&A background on how this research came about, findings that particularly surprised her, and how these findings are guiding current and future initiatives. ow.ly/45XQ50Z6X0I

The May issue of ASTCT's journal, 'Transplantation and Cellular Therapy,' is now available online: astctjournal.org/current @ELShematology @ASTCT_Journal

How is the role of upfront BMT changing for patients with severe aplastic anemia? Join us tomorrow for a webinar reviewing current evidence, patient selection, donor sources, conditioning strategies and practical case-based considerations. Register: ow.ly/5Nx550Z6WZr

Stay current on emerging evidence in transplantation and cellular therapy. At the next ASTCT Pharmacy Journal Club, presenters will review data from the ATLAS trial evaluating KRd maintenance after ASCT in multiple myeloma and the ZUMA-2 Cohort 3 analysis of brexucabtagene autoleucel in BTKi-naive relapsed/refractory mantle cell lymphoma. Register: learn.astct.org/products/ast…

This review article highlights how regulatory T cells can suppress acute and chronic #GVHD while preserving graft-versus-leukemia effects after #alloHCT. Early clinical studies demonstrate promising GVHD control low relapse rates and favorable survival. ow.ly/U4PY50Z5OMO

Check out our recent collaborative X space discussion with @CancerNetwrk highlighting key hematologic oncology findings from ASCO 2026. @ASCO x.com/i/spaces/1DGleeXwrQrJL…

With the launch of our new strategic plan, mission and vision, ASTCT is strengthening our commitment to advancing hematopoietic cell transplantation (HCT) and cellular therapy. There's no better time than now to join. For a limited time, join between June 1 and September 30 and receive membership through December 31, 2027. Learn more: ow.ly/zMp150Z6rLY

This perspective article shows that TBF conditioning for #alloHSCT offers potent disease control in acute leukemias and myeloproliferative neoplasms. Dose tailoring therapeutic drug monitoring and patient selection may mitigate toxicity. Read more: ow.ly/ZrwC50YYtGb

ASTCT is proud to introduce an updated mission and vision reflecting its leading role in the field of hematopoietic cell transplantation and cellular therapy. Our new guiding statements capture our commitment to advancing research, education, and clinical excellence for our patients. Aligned with ASTCT’s strategic pillars — influence, innovation and growth — the updated mission and vision outline a clear direction for our Society's work and future. Learn more: ow.ly/MQ7150Z2V6T

Researchers at @MSKCancerCenter and @cityofhope, together with a multicenter U.S. team and Poseida Therapeutics, have reported early clinical activity for a prostate-specific membrane antigen (PSMA)-directed CAR T-cell therapy in metastatic castration-resistant prostate cancer (mCRPC). Read more: ow.ly/YWyl50Z2v4k

Applications are open for the 2026 International Trainee Observership Program. One international trainee from a low/mid-income country will participate in a 4-week-long observership at @thisisUIC and attend #Tandem27. 📆 Deadline to apply: Sunday, May 24 🔗 ow.ly/60cF50YQIiW